BDS is continuously working on new CALUX^® and other bioassay pipeline technology for the measurement of trace materials.  Current pipeline that we can currently reveal includes:


> an ERalpha receptor mediated CALUX^® assay
> progestin receptor mediated CALUX^® assay
> bioassay for thyroid hormones 

If you have interest in any of the above areas, please contact us. Your input may contribute to our research and would be much appreciated. BDS is continually trying to improve its CALUX assays and is currently engaged in researching improved techniques for automated sample work-up, wider application, reduced analysis time and other initiatives.